- Home
- KD vs PCVX Comparison
KD vs PCVX Comparison
Compare KD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KD | PCVX |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KD | PCVX |
|---|---|---|
| Price | $23.01 | $54.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $39.60 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 02-09-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $15,008,000,000.00 | N/A |
| Revenue This Year | $6.40 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.79 | $27.66 |
| 52 Week High | $44.20 | $92.59 |
Technical Indicators
Market Signals| Indicator | KD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 27.72 | 65.69 |
| Support Level | $24.24 | $50.50 |
| Resistance Level | $24.72 | $55.11 |
| Average True Range (ATR) | 0.77 | 2.94 |
| MACD | -0.31 | 0.55 |
| Stochastic Oscillator | 4.29 | 88.14 |
Price Performance
Historical ComparisonAbout KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.